Welcome to Ligand Pharmaceuticals

Ligand is a high-growth company with economic rights to some of the world's most important medicines.

Portfolio
Technologies
Licensing Opportunities

Investor Relations

View Investor Relations

Latest News

Ligand’s Partner Melinta Therapeutics Announces U.S. FDA Approval of Baxdela™ (Delafloxacin) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Read More

Ligand Enters into Worldwide OmniAb® Platform License Agreement with Surface Oncology

Read More

Ligand Announces Aziyo Biologics Acquires Commercial Products from Partner CorMatrix

Read More

Recent Events

Stock Snapshot

LGND
NASDAQ
Volume
Market Cap
Day Range
52-Week Range